Clinical trial NCT05236608 - References

Metastatic Non Small Cell Lung Cancer — A Study to Evaluate the Combination of Nivolumab With ADG106 in Metastatic NSCLC

Citation(s)

•   Costantini A, Corny J, Fallet V, Renet S, Friard S, Chouaid C, Duchemann B, Giroux-Leprieur E, Taillade L, Doucet L, Nguenang M, Jouveshomme S, Wislez M, Tredaniel J, Cadranel J
  Efficacy of next treatment received after nivolumab progression in patients
•   Freeman AT, Lesperance M, Wai ES, Croteau NS, Fiorino L, Geller G, Brooks EG, Poonja Z, Fenton D, Irons S, Ksienski D
  Treatment of non-small-cell lung cancer after progression on nivolumab or pembrolizumab. Curr Oncol. 2020 Apr;27(2):76-82. doi: 10.3747/
•   Qi X, Li F, Wu Y, Cheng C, Han P, Wang J, Yang X
  Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with Fc?R affinity. Nat Commun. 2019 May 20;10(1):2141. doi: 10.1038/s41467-019-10088-1.
•   Sanchez-Paulete AR, Labiano S, Rodriguez-Ruiz ME, Azpilikueta A, Etxeberria I, Bolaños E, Lang V, Rodriguez M, Aznar MA, Jure-Kunkel M, Melero I
  Deciphering CD137 (4-1BB) signaling in T-cell costimulation for translation into successful cancer immunother

A Phase 1b/2 Study to Evaluate the Combination of Nivolumab (Anti PD1 Monoclonal Ab) With ADG106 (4-1-BB Agonist Monoclonal Ab) in Metastatic NSCLC After Progression With antiPD1 Therapy and Platinum-based Chemotherapy (ADIVO Lung Study)

Details for clinical trial NCT05236608